Inga Peter, PhD Email Inga Peter
- PROFESSOR | Genetics and Genomic Sciences
Diabetes, Genetics, Genomics, Obesity
Multi-Disciplinary Training Area
Genetics and Data Science [GDS]
MSc, Tel Aviv University
PhD, Tel Aviv University
, Tufts University
, Weizmann Institute of Science
My research focus is in identifying genes involved in complex disorders that include hypertension, cardiovascular disease, obesity, diabetes, and Crohn's disease. I am particularly interested in genetic control of estrogen metabolism and action. My colleagues and I identified genetic variations in estrogen receptor genes (ESR1 and ESR2) that are associated with increased prevalence of myocardial infarction and other cardiovascular risk factors. In addition, I am interested in finding genes that influence vascular reactivity, arterial stiffness and are associated with the risk of atherosclerosis and hypertension. My general approach is to apply candidate gene and genome-wide association studies, or GWAS, to detect genotype-phenotype associations in large cohorts of individuals.
Most recently, I started to investigate genetic influences on responsiveness to treatments. I lead a pharmacogenetic study of an ongoing randomized clinical trial aimed to provide myocardial metabolic support in the form of intravenous Glucose-Insulin-Potassium (GIK) therapy to individuals with acute coronary syndrome. IMMEDIATE (Immediate Myocardial Metabolic Enhancement During Initial Assessment and Treatment in Emergency care) Trial is currently in the process of recruiting patients nation-wide and comparing immediate and long-term response to treatment versus placebo with regard to myocardial function. Given accumulating evidence strongly suggesting that mutations in genes encoding drug targets can be linked to drug responses, we hypothesize that variations in genes encoding common pathways related to GIK response in the heart will be associated with the immediate and long-term response to GIK therapy. Another project is aimed to identify variation in genes that are members of the G-coupled protein receptor (GPCR) family associated with diabetes and obesity. The major study cohort isthe Look AHEAD study (Action for HEAlth in Diabetes), a clinical trial conducted in 16 centers in the US investigating the long-term health impact of an intensive lifestyle intervention in overweight and obese adults with type 2 diabetes. So far, the trial completed its 1-year follow-up that showed that intensive lifestyle intervention resulted in clinically significant weight loss, which was associated with improved diabetes control and CVD risk factors. The next step will be to investigate whether these phenotypes correlate with GPCR genotype data. We expect to see that carriers of certain genotypes will be more likely to lose and maintain low weight over time.
Finding genes associated with complex disorders may help elucidate mechanisms of disease pathogenesis and enhance our ability to postpone and treat these conditions in genetically susceptible individuals before irreversible clinical manifestations occur.
I also serve as the Principal and co-Investigator on a number of projects that involve Mount Sinai Biobank participants.
I am the co-Investigator of the NHGRI-funded U01 grant ‘Biorepositories for Genomic Medicine in Diverse Communities’ (eMERGE) and the Institute of Personalized Medicine - funded grant ‘Evaluating Information Needs to Generate Community Engagement and Genomics Education’ (ENGAGE). I also lead two pilot studies focused on the Mount Sinai Biobank population: 1) to determine genetic variants associated with type 2 diabetes in the absence of obesity and 2) to identify differences in microbial content between obese and lean diabetics. In addition, I am the Principal Investigator of the National Heart, Lung and Blood Institute - funded R01 grant aimed to identify genetic factors associated with response to metabolic therapy in a setting of acute coronary syndrome. Furthermore, I am leading the laboratory research on mechanisms of Crohn’s disease.
- Genetics of complex diseases through next generation sequencing
- Pharmacogenetics and genetic risk modification by means of lifestyle intervention
- Microbiome studies of Crohn’s disease, type 2 diabetes, and obesity
- Population genetics of Ashkenazi Jews
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Peter has not yet completed reporting of Industry relationships.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.